Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Bode

Showing results (171-180 of 176) with videos related to

Pageof 18
Sort By:
You have reached the last page of results.This site can display upto 176 results.
European Journal of Human Genetics : EJHG|March 28, 2019
Phenotypic spectrum associated with a CRADD founder variant underlying frontotemporal predominant pachygyria in the Finnish populationDaniel L Polla, Elisa Rahikkala, Michaela K Bode, et al.
Urologic Oncology|March 26, 2013
Ensuring comprehensive assessment of urinary problems in prostate cancer through patient-physician concordanceDavid E Victorson, Penny S Brucker, Rita K Bode, et al.
Science Advances|February 8, 2023
Single-cell profiling of alveolar rhabdomyosarcoma reveals RAS pathway inhibitors as cell-fate hijackers with therapeutic relevanceSara G Danielli, Ermelinda Porpiglia, Andrea J De Micheli, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|February 20, 2020
CD90<sup>+</sup>CD146<sup>+</sup> identifies a pulmonary mesenchymal cell subtype with both immune modulatory and perivascular-like function in postnatal human lungLimei Wang, Patrick Dorn, Soheila Zeinali, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2022
Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology GroupDavid Milewski, Hyun Jung, G Thomas Brown, et al.
Cancer Cell|February 12, 2015
Mutations in the SIX1/2 pathway and the DROSHA/DGCR8 miRNA microprocessor complex underlie high-risk blastemal type Wilms tumorsJenny Wegert, Naveed Ishaque, Romina Vardapour, et al.
Pageof 18

Showing results (171-180 of 176) with videos related to

Sort By:
Pageof 18
You have reached the last page of results.This site can display upto 176 results.
European Journal of Human Genetics : EJHG|March 28, 2019
Phenotypic spectrum associated with a CRADD founder variant underlying frontotemporal predominant pachygyria in the Finnish populationDaniel L Polla, Elisa Rahikkala, Michaela K Bode, et al.
Urologic Oncology|March 26, 2013
Ensuring comprehensive assessment of urinary problems in prostate cancer through patient-physician concordanceDavid E Victorson, Penny S Brucker, Rita K Bode, et al.
Science Advances|February 8, 2023
Single-cell profiling of alveolar rhabdomyosarcoma reveals RAS pathway inhibitors as cell-fate hijackers with therapeutic relevanceSara G Danielli, Ermelinda Porpiglia, Andrea J De Micheli, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|February 20, 2020
CD90<sup>+</sup>CD146<sup>+</sup> identifies a pulmonary mesenchymal cell subtype with both immune modulatory and perivascular-like function in postnatal human lungLimei Wang, Patrick Dorn, Soheila Zeinali, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2022
Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology GroupDavid Milewski, Hyun Jung, G Thomas Brown, et al.
Cancer Cell|February 12, 2015
Mutations in the SIX1/2 pathway and the DROSHA/DGCR8 miRNA microprocessor complex underlie high-risk blastemal type Wilms tumorsJenny Wegert, Naveed Ishaque, Romina Vardapour, et al.
Pageof 18